A population pharmacokinetic analysis was performed in 30 patients who received an intravenous busulfan and cyclophosphamide regimen before hematopoietic stem cell transplantation. Each patient received 0.8 mg/kg as a 2 h infusion every 6 h for 16 doses. A total of 690 concentration measurements were analyzed using the nonlinear mixed effect model (NONMEM) program. A onecompartment model with an additive error model as an intraindividual variability including an interoccasion variability (IOV) in clearance (CL) was sufficient to describe the concentration-time profile of busulfan. Actual body weight (ABW) was found to be the determinant for CL and the volume of distribution (V) according to NONMEM analysis. In this limited study, the age (range 7-53 years old; median, 30 years old) had no significant effect on busulfan pharmacokinetics. For a patient weighting 60 kg, the typical CL and V were estimated to be 8.87 l/h and 33.8 l, respectively. The interindividual variability of CL and V were 13.6 and 6.3%, respectively. The IOV (6.6%) in CL was estimated to be less than the intraindividual variability. These results indicate high interpatient and intrapatient consistency of busulfan pharmacokinetics after intravenous administration, which may eliminate the requirement for pharmacokinetic monitoring.
Introduction
A high dose of busulfan in combination with cyclophosphamide is a widely used myeloablative conditioning regimen before both allogenic and autologous bone marrow transplantation (BMT). 1, 2 In most cases, busulfan is administered every 6-h over four consecutive days with a total standard dose of 16 mg/kg. 1 As with most alkylating agent, busulfan has a narrow therapeutic window. The dose-limiting toxicity of busulfan in the myeloablative conditioning regimen is hepatic veno-occlusive disease (VOD), which can lead to fatal liver failure. 3, 4 Following administration of the oral formulation, very wide inter-and intraindividual systemic exposure has been reported, 5 which may be linked to erratic intestinal absorption, variable hepatic metabolism, circadian rhythm, genetics, diagnosis, drug-drug interaction and age. [5] [6] [7] [8] [9] Recently, the intravenous formulation of busulfan has been developed in order to minimize variations of the inter-and intrainidividual systemic exposure and to provide complete dose assurance. The intravenous busulfan is registered in the USA (Busulfext) and in Europe (Busilvext) for adults. The recommended dosage was 0.8 mg/kg/dose for 16 consecutive doses in adults. [10] [11] [12] There have been several reports about intravenous busulfan pharmacokinetics, [10] [11] [12] [13] with only a few applying population pharmacokinetic analysis. 13 We report here, the results of the population pharmacokinetic modeling of intravenous busulfan. The aim of this analysis was to characterize the pharmacokinetics of intravenous busulfan, including the IOV and covariate relationships in patients.
Materials and methods

Patients
A total of 30 Japanese patients (27 adults and three children) receiving a first BMT entered in a Phase 2 study were investigated. These patients received busulfan at 0.8 mg/kg as a 2 h infusion every 6 h for four consecutive days. Following busulfan therapy, patients were given cyclophosphamide at 60 mg/kg as a 3 h infusion daily for 2 days. In order to prevent seizures, phenytoin (5-10 mg/kg/day) was administered orally for 8 days, starting 2 days before the start of busulfan therapy. The following demographic and physiopathological data were considered in the analysis: diagnosis, acute myeloid leukemia (13) , acute lymphocytic leukemia (5), chronic myelogenous leukemia (5), myelodysplastic syndrome (3), non-Hodgkin's lymphoma (4); gender, male (20) (27) , yes (3); concomitant antifungal treatment, no (7), yes (23); concomitant 5-HT 3 antiemetic treatment, no (16) , yes (14) . The study was approved by an independent Ethical Committee at each center. All patients provided written informed consent before enrollment.
Pharmacokinetic sampling and busulfan determination Serial blood samples were drawn from each patient immediately before the first and ninth busulfan dose and then 0.25, 0.5, 0.75, 1.92, 2.25, 2.5, 3, 4, 5 and 6 h after the start of the first and ninth dose. The 13th dose sampling of each patient was made immediately before the infusion and at 1.92 h from the start of infusion, respectively. Plasma samples obtained by centrifugation were stored frozen until analysis. Busulfan was assayed by a validated gas chromatographic-mass selective detection (GC-MSD) assay technique.
14 The calibration curves were linear over concentrations ranging from 62.5 (quantification limit) to 2000 ng/ml. Samples with a concentration higher than 2000 ng/ml were diluted such that the concentration fell within the range of the calibration curve. Acceptance criteria for validating the analytical results of each run were as follows. Quality control (QC) samples in duplicate at three concentrations (125, 500, and 1500 ng/ml) were incorporated into each run. The results of the QC samples provided the basis for accepting or rejecting the run. At least four of six QC samples had to be within 720% of their respective nominal values, and two of six QC samples (both at the same concentration) had also to be within the 720% respective nominal value. The GC-MSD for pharmacokinetic investigation was performed at BML Inc. (Saitama, Japan). A total of 690 concentration measurements were available.
Population pharmacokinetic analysis and model validation Data were analyzed using the nonlinear mixed effect model (NONMEM) program (version 5.0, Globomax LLC, Hanover, MD, USA). As the population pharmacokinetic model is used for prediction, it is important to develop a model with validation. 15 Owing to the limited number of patients in this study, external validation of the population pharmacokinetic model could not be applied; therefore, the model was evaluated using bootstrapping, one of the internal validation techniques. 15, 16 Population pharmacokinetic modeling steps were as follows: (1) a basic pharmacokinetic modeling using the NONMEM program and obtaining Bayesian individual parameter estimates, (2) validation of a basic model using the bootstrap resampling technique, (3) generalized additive modeling (GAM) for the selection of covariate candidates, (4) final pharmacokinetic modeling to determine the covariate model, and (5) validation of the final model. The NONMEM program and PREDPP package were used throughout the analysis. The first-order conditional estimation with interaction method was used in all analysis processes because of the extensive sampling design in the study. Initial pharmacokinetic parameter estimates for NONMEM modeling were calculated using the mean data obtained from all the patients by WinNonlin (version 3.3, Pharsight Corp., Mountain View, CA, USA).
Step 1: basic pharmacokinetic modeling without bootstrapping. One-compartment structural model with constant rate infusion was fitted to the busulfan concentration-time data. Interindividual variability in clearance (CL) was modeled using an exponential error model, as follows:
where CL i represents the hypothetical true CL for the ith individual, CL is the typical population value of CL and Z is independent, identically distributed random variables with mean 0 and variance o 2 . Interindividual variability in volume of distribution (V) was similarly modeled.
Residual intraindividual variability was identically distributed and was modeled using the additive error, constant coefficient of variation (CCV) error or the combination of the additive and CCV error models. The additive error model is described by the following equation:
where Cp ij is the ith measured concentration in the jth individual and Cp mij is the ith concentration predicted by the model at the ith observation time for the jth individual. e is independent random variable with mean zero and variance s 2 . The magnitude of residual intraindividual variability usually depends on measurement, dosing, sampling and model misspecification errors.
IOV was introduced into the model as previously proposed. 17 The following expression was used for CL
where CL ij represents the hypothetical true CL for the ith individual at occasion j, CL is the typical population value of CL and Z and k are independent, identically distributed random variables both with mean 0 and variance o 2 and p 2 , respectively. IOV in V was similarly modeled.
With the fixed and random effects chosen, empirical Bayes estimates of pharmacokinetic parameters were subsequently obtained using POSTHOC option within the NONMEM program. The choice of a basic population model was based on monitoring the Akaike's information criterion (AIC). The reliability of the model selection was checked by the analysis of residual and by the visual inspection of plots of predicted versus measured concentrations.
Step 2: validation of a basic model using the bootstrap resampling technique. Resampling the original data with replacements generated 100 bootstrap samples. The resampling unit comprises samples obtained from each Population pharmacokinetics of intravenous busulfan H Takama et al patient. The appropriate structural model that best describes the data from each sample was determined. This was performed to ensure that the model, which best described the bootstrap data was not different from the basic used for developing the population pharmacokinetic model in the subsequent step. In addition, density plots of each pharmacokinetic parameter estimate were used to examine the adequacy of the basic model.
Step 3: selection of covariate candidates. Exploratory data analysis was performed on the empirical Bayesian parameter estimates from step 2 and treated as data to examine the distribution, shapes and relationships between covariates and individual pharmacokinetic parameter estimates. The data were subjected to a stepwise (single term addition/deletion) procedure using the GAM procedure in the Xpose program (version 3.1) 18 running on the S-PLUS statistical software package (version 6.0, Insightful Corp., Seattle, WA, USA). Each covariate was allowed to enter the model in any of several functional representations. AIC was used for model selection. 19 At each step, the model was changed by the addition or deletion of the covariate that results in the largest decrease in AIC. The search was stopped when AIC reached a minimum value.
Step 4: population model building using NONMEM. For each NONMEM analysis, the improvement in fit obtained upon the addition of a covariate selected from step 3 to the regression model was assessed by changes in the NONMEM objective function. Minimization of the NONMEM objective function, equal to twice the negative log-likelihood of the data, is equivalent to maximizing the probability of the data. The change in the objective function of the NONMEM value is approximately w 2 distributed. A difference in the NONMEM objective function value of 3.84, associated with a P-value of less than 0.05, was considered statistically significant.
The construction of the regression model for each structural model parameter was performed in three steps using the original data set. Covariates were first screened individually. The full model was then defined as incorporating all significant covariates. Lastly, the final model was elaborated by backward elimination from the full model.
Step 5: validation of the final population pharmacokinetic model. Two hundred bootstrap samples were generated by resampling with replacements and used for the evaluation of the stability of the final model built in step 4. The final population pharmacokinetic model was fitted repeatedly to the 200 additional bootstrap samples. The mean parameter estimates obtained from these bootstrap replications were compared with those obtained from the original data set.
The area under the plasma concentration-time curve The area under the plasma concentration-time curve (AUC) in each patient was calculated according to the linear trapezoidal rule using WinNonlin. The AUC at the steady state was calculated for the ninth dose from dosing interval (from zero to last sampling time). The AUC in one of 30 patients after the ninth administration was not calculated because the last sample at the ninth dose was collected after the start of the next dose.
Results
Determination of a basic pharmacokinetic model
Plasma concentration versus time curves are shown in Figure 1 . Parameter estimates of various structural models are given in Table 1 . The models including IOV gave lower AIC values than the models not including IOV. The Additive model, including IOV and the combination of the additive and CCV error models (the combination error model) including IOV gave similar AIC values. Analysis of residuals and plots of observed versus predicted concentrations were performed to check the reliability of the basic model selection. The residuals calculated in the additive model including IOV were not obviously different from those obtained in the combination error model including IOV (data not shown). The stability of these two models was examined in a subsequent step.
Stability of the basic model as assessed using the bootstrap resampling technique
One hundred bootstrap replicates were generated from the original data and used for the evaluation of the stability of The parameter estimates could be obtained from all bootstrap data sets using the additive error model including IOV; however, one of 100 bootstrap data sets using the combination error model including IOV did not result in convergence. It was found that the additive model including IOV was more stable than the combination error model including IOV. Each parameter distribution of the additive error model including IOV is in a narrow range and almost unimodal (data not shown). Therefore, the additive error model including IOV was selected as the optimum basic model and was used in subsequent steps. Parameter estimates of the basic model are given in Table 2 . As can be seen, the value of IOV in V is small, the decision was made whether the IOV introduces into V or not in subsequent steps. Plots of observed versus predicted concentration for the basic model are shown in Figure 2a .
Selection of covariate candidates GAM analysis indicated that CL and V are functions of ABW (data not shown).
Population model building and stability of the final population models
The population model with covariates was built using the NONMEM program on the basis of the result of GAM analysis. ABW was found to be the predictor of both CL and V with a log-likelihood difference (LLD) of more than 10.83 (Po0.001) between each model in which ABW was introduced singly, and the basic model of each pharmacokinetic parameter modeled without ABW (data not shown). The full regression model was that following the allometric equations:
, where y 1 and y 3 are the population values of CL and volume of distribution for the 60-kg patients. The IOV was not introduced into V in the population model since the IOV values obtained from each covariate model were negligible and the other parameter estimates were not changed by the introduction of IOV in V (data not shown). The full model was tested against the reduced models ( Table 3) .
The final population pharmacokinetic model obtained from the previous step was fitted repeatedly to the 200 bootstrapped samples. The parameter estimates of the final model using the original data and the mean parameter estimates obtained from the 200 bootstrap replicates are provided in Table 4 . The mean parameter estimates were within 15% of those obtained with the original data set. Plots of observed versus predicted concentrations for the final model are shown in Figure 2b . Plots of individual parameter values obtained from the model-independent technique versus ABW are shown in Figure 3 . The final 
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Population pharmacokinetics of intravenous busulfan H Takama et al population model was well described the relationships between the pharmacokinetic parameters and ABW.
Discussion
The objective of population pharmacokinetic analysis was to characterize the pharmacokinetics of the intravenous busulfan including IOV and covariate relationships in patients. Reliability of results obtained from population analyses depends on the modeling procedure. Therefore, the evaluation of basic (covariate-free model) and final (covariate model) population pharmacokinetic models was performed using bootstrap resampling because of the limited number of patients in the study.
The one-compartment model with an additive error model including IOV in CL was selected as the population model during model development. The final population pharmacokinetic model built in the study was fitted to the 200 bootstrap samples. The mean parameter estimates obtained with the 200 bootstrap replicates of the data were within 15% of those obtained from original data. This indicates that the final model is stable.
With regard to the effect of covariates investigated in this analysis on the pharmacokinetic parameters of busulfan after intravenous infusion, the ABW was found to be a determinant of CL and V. In the previous studies, age, ABW, body surface area (BSA), ALT and concomitant phenytoin treatment were reported as possible covariates of oral busulfan pharmacokinetics. [5] [6] [7] [8] [9] 20, 21 After the intravenous administration of busulfan, the relationships between ABW and pharmacokinetic parameters were reported. 13 Since physiological function was relatively well controlled in our study, variation of covariates was in a narrow range or within the normal limits. The limitation of developing population models based on such a small, relatively uniform patient population has been reported. 22 Therefore, the relationships between covariates and the pharmacokinetic parameters of intravenous busulfan need further investigation in a larger population, especially in younger children.
In general, a nomogram based on the population approach is a useful tool for dose adjustment, and therapeutic drug monitoring (TDM) is another powerful ABW, actual body weight. Clearance (CL) (a) and the volume of distribution (V) (b) after the first administration were calculated according to noncompartmental analysis using WinNonlin. Lines represent the estimates predicted the proposed allometric equations. Open and closed circles represent the value in adults and children, respectively. To compare our data with the oral busulfan studies in adult patients, we used previously published data. 23 The selected study has similar sampling points to our study and individual AUC were reported. Several reports indicate that an AUC of 900-1500 mmol min/l 4, 6, 24, 25 in patients receiving a conventional busulfan regimen prevents treatment failure and the risk of fatal toxicities. In the previous study, the observed AUC at a steady state in 8/12 (66.7%) patients without dose adjustment fell in the above range. The percentage of patients within the range increased to 92.9% (13/14) with the dose adjustment according to the TDM results. In our study, the observed AUCs at steady state in 25/29 (86.2%) patients were within the range.
TDM requires blood sampling, drug concentration measurement and pharmacokinetic analysis. In the case of TDM after the administration of busulfan, it takes 1 or 2 days to adjust the dosage regimen using TDM data. Therefore, 25-50% of busulfan exposure remains uncontrollable in the standard regimen of 16 doses four times per day for 4 days. The contribution of the TDM for busulfan therapy is limited because of the reason described above. Intravenous busulfan may have an advantage over the oral busulfan in the limited term therapy since the systemic exposure of intravenous busulfan is expected to be reproducible throughout the treatment as compared with that of oral busulfan with TDM.
Oral busulfan is generally used at a dose of 1 mg/kg in adults, but the recommended dosage of intravenous busulfan is 0.8 mg/kg. [10] [11] [12] The previous report suggests that 1 mg/kg oral busulfan is a slight over-dosage. 27 According to the previous report, the benefit of the intravenous busulfan administration is not only the decrease in the variability of systemic exposure (AUC), but also the optimizing of average exposure during busulfan dosing. 28 In order to come to a definite conclusion of the clinical benefit of the intravenous busulfan, a prospective comparison of exposure of intravenous versus oral administration might be needed.
